



Execution of complex Bayesian workflows with the DDMoRe Interoperability Framework: a case study in the diabetes area

C. Larizza¹, E. Borella¹, L. Pasotti¹, P. Tartaglione¹, M. Smith², S. Moodie³, P. Magni¹

(1) Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Pavia, Italy;

(2) Dept Statistical Pharmacometrics, Pfizer Global Research & Development, UK; (3) Eight Pillars Ltd, Edinburgh, UK

BACKGROUND. The DDMoRe Interoperability Framework (IOF) [1] can execute a desired model using different target tools, requiring a single model encoding effort, through Modelling Description Language (MDL) and the R *ddmore* package. The interoperability is based on two system-to-system interchange standards: the Pharmacometrics Markup Language (PharmML) [2] and the Standard Output (SO) [3].

OBJECTIVE. We integrated WinBUGS, a popular Bayesian estimation tool, in the IOF (downloadable at [4]) and we demonstrated its use to design and execute a complex interoperable modelling workflow, based on two diabetes-related models.

MATERIALS AND METHODS.

SOFTWARE MODULES DEVELOPED


1. PharmML-to-BUGS converter, supporting:

- Algebraic/ODE/PKMacro models
- Multiple variability levels (with pairwise covariance/correlation)
- Single/multiple (independent/correlated) observations
- Univariate/multivariate parametric/non-parametric/empirical distributions
- (Transformed) continuous/categorical covariates
- IF-THEN-ELSE statements
- Matrices/vectors

2. NMTRAN-to-BUGS data converter

3. BUGS output-to-SO converter

4. WinBUGS connector



DIABETES-RELATED MODELS

- Population regression model to estimate CP kinetic parameters [5]

$$\begin{aligned} \mathbf{M0} \quad & \theta_i = \begin{pmatrix} ts \\ F \\ V \\ tl \end{pmatrix} = f(\tilde{\theta}, \mathbf{U}_i) \\ & \text{with } \mathbf{U}_i = \begin{pmatrix} \text{Hstatus} \\ \text{BSA} \\ \text{Sex} \\ \text{Age} \end{pmatrix} \\ & \phi_i = \theta_i + \eta_i \\ & \eta_i \sim N(0, \Sigma) \\ & + \\ & \tilde{\theta} \sim N(\tilde{\theta}_0, \Sigma_0^{-1}) \\ & \Sigma^{-1} \sim W(\rho, \mathbf{R}) \end{aligned} \quad \mathbf{M4}$$


- Glucose-insulin minimal model (MM)[6] to estimate physiologically-relevant insulin secretion indexes

$$\begin{aligned} & \frac{dCP_1(t)}{dt} = -(k_{01} + k_{21})CP_1(t) + k_{12}CP_2(t) + mX(t) \\ & \frac{dCP_2(t)}{dt} = -k_{12}CP_2(t) + k_{21}CP_1(t) \\ & CP_1(0) = CP_2(0) = 0 \\ & \frac{dX(t)}{dt} = -mX(t) + Y(t) \\ & \frac{dY(t)}{dt} = \begin{cases} -\alpha(Y(t) - \beta(G(t) - h)) & \text{if } G(t) > h \\ -\alpha Y(t) & \text{otherwise} \end{cases} \\ & X(0) = x_0, Y(0) = 0 \end{aligned}$$

Insulin secretion indexes

$$\begin{aligned} \phi_1 &= \frac{x_0}{\Delta G} \\ \phi_2 &= \beta \\ \text{ISR} &= mX(t) \end{aligned}$$

IMPLEMENTED COMPLEX WORKFLOW



RESULTS. Parameters estimates obtained at points 1) and 3) were consistent with the published values, which were originally obtained via Matlab.

- Population regression model (M4)


	mtsn (min)	mtso (min)	mtsd (min)	mFn (-)	mFo (-)	mFd (-)	atl (min)	btl (min/yr)	aVm (L)	aVf (L)	bVm (L/m ²)	bVf (L/m ²)
Matlab	4.99	4.50	4.70	0.767	0.781	0.778	26.70	0.209	0.417	0.89	2.04	1.77
BUGS	4.99	4.50	4.69	0.765	0.781	0.778	26.71	0.209	0.341	0.83	2.06	1.80

	VAR_ts (min ²)	VAR_F (-)	VAR_tl (min ²)	VAR_V (L ²)	COV_ts_F (min)	COV_ts_tl (min ²)	COV_ts_V (min L)	COV_F_tl (min)	COV_F_V (L)	COV_tl_V (min L)
Matlab	1.30	0.0022	32.94	0.71	0.0062	3.24	0.59	0.071	-0.0055	1.89
BUGS	1.30	0.0022	33.04	0.71	0.0062	3.24	0.59	0.071	-0.0057	1.91

- Glucose-insulin minimal model (MM)

	h (pmol/L)	ϕ_1 (-)	ϕ_2 (1/min)	m (1/min)	α (1/min)
Matlab	88.83	85.6	10.07	0.73	0.044
BUGS	89.16	88.5	10.93	0.79	0.050

The insulin secretion indexes indicate the β -cell sensitivity to glucose in the first fast release (ϕ_1) and in the second slower release (ϕ_2) after an IVGTT, and the time course of insulin secretion rate (ISR).



REFERENCES.

- <http://www.ddmore.eu/official-release-interoperability-framework>
- Swat MJ et al. (2015). Pharmacometrics Markup Language (PharmML): Opening new perspectives for model exchange in drug development. CPT Pharmacometrics Syst. Pharmacol. 4, 316-319.

[3] PAGE 25 (2016) Abstr 5954 [www.page-meeting.org/?abstract=5954]

[4] <https://sourceforge.net/projects/ddmore/files/install/SEE/>

[5] Magni P et al. (2000). Bayesian identification of a population compartmental model of C-peptide kinetics. Ann. Biomed. Eng. 28(7), 812-823

[6] Magni P et al. (2004). Insulin minimal model indexes and secretion: Proper handling of uncertainty by a bayesian approach. Ann. Biomed. Eng. 32(7), 1027-1037.